Betsy Wernli, MD
Dermatology · Manitowoc, WINPI 1437378973
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $132,101 of the $177,262 with a category attached, or 74.5%. AbbVie accounts for 79.3% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $97,830 and has fallen 99.2% since, to $775 in 2025. Among dermatology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 386 payments — averaging $459.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$141K
- UCB, Inc.$33K
- Johnson & Johnson$812
- Novartis$563
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$303
- Lilly USA, LLC$287
- plus $2K from 25 others
What the payments were for
- Consulting fees$28,95016%
- Speaking & faculty fees$132,10175%
- Travel & lodging$9,8496%
- Food & beverage$6,1303%
- Education$2320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 118 | $140,606 |
| UCB, Inc. | 69 | $32,501 |
| Johnson & Johnson | 35 | $812 |
| Novartis | 34 | $563 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $303 |
| Lilly USA, LLC | 15 | $287 |
| Sanofi | 11 | $244 |
| Dermavant Sciences, Inc. | 3 | $216 |
| Sun Pharmaceutical Industries Inc. | 13 | $203 |
| E.r. Squibb & Sons, L.L.C. | 9 | $170 |
| Biofrontera Inc. | 7 | $156 |
| Incyte Corporation | 8 | $155 |
| Regeneron Healthcare Solutions, Inc. | 7 | $151 |
| Organon | 1 | $125 |
| Bristol Myers Squibb | 11 | $121 |
| Arcutis Biotherapeutics, Inc. | 5 | $110 |
| Amgen | 6 | $104 |
| Galderma Laboratories, L.p. | 5 | $74 |
| Genentech USA, Inc. | 4 | $64 |
| Boehringer Ingelheim | 3 | $59 |
| Pfizer | 1 | $42 |
| Kyowa Kirin, Inc. | 1 | $33 |
| LEO Pharma Inc. | 1 | $21 |
| Mimedx Group, Inc. | 1 | $20 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $19 |
| Strata Skin Sciences, Inc. | 3 | $19 |
| Almirall LLC | 1 | $19 |
| Prugen, Inc. Pharmaceuticals | 2 | $17 |
| Nobelpharma America, LLC | 1 | $16 |
| Pierre Fabre Pharmaceuticals, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$177,262 in reported general payments places this provider in the 95th percentile of 260 dermatology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 39 | $191,961 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $85,516 |
| RinvoqUpadacitinib | 12 | $75,936 |
| Dupixent PenDupilumab | 14 | $57,634 |
| Clobetasol Propionate | 171 | $6,968 |
| Ketoconazole | 108 | $2,587 |
| Fluorouracil | 20 | $2,132 |
| Fluocinonide | 50 | $1,534 |
| Triamcinolone Acetonide | 126 | $1,270 |
| Betamethasone Dipropionate | 13 | $1,188 |
| Hydroxychloroquine Sulfate | 28 | $789 |
| Doxycycline Monohydrate | 30 | $723 |
| Clindamycin Phosphate | 24 | $719 |
| Metronidazole | 13 | $472 |
| ValacyclovirValacyclovir Hcl | 14 | $448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $104 | $191,96139 claims |
| AbbVieRinvoq | $140,606 | $75,93612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 260 dermatology providers in Wisconsin.
Other dermatology in Manitowoc
- Azam QureshiManitowoc$11K
- Kyung Ai ChaeManitowoc$2K
- David NelsenJanesville$1.1M
- Gabriela MaloneyOconomowoc$725K
- Kenneth GordonWauwatosa$577K
- Ashley DietrichMilwaukee$466K
- Martin OkunFort Atkinson$232K
- Daniel OpelSheboygan$118K
- Stephen LewellisPlover$73K
- Patrick SafoStevens Point$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.